“Increased R&D investment for rare genetic disorders”
One significant trend driving market growth is increased investment in R&D for rare genetic disorders, including Hurler Syndrome, has spurred innovation and the development of new therapeutic options, further propelling market growth. For instance, The EU has invested in rare disease research for two decades, with over USD 3.4 million invested from 2007 to 2020. Such funding supports the exploration of novel therapies, such as gene therapy and substrate reduction therapies, which have shown promising results in preclinical trials. Additionally, pharmaceutical companies such as Sanofi and Regenxbio are actively investing in developing new treatments for Hurler Syndrome, highlighting the growing interest and financial commitment in advancing therapeutic options for Mucopolysaccharidosis.
